Teshome Shibre1, Girmay Medhin2, Atalay Alem3, Derege Kebede4, Solomon Teferra3, Lars Jacobsson5, Gunnar Kullgren5, Charlotte Hanlon6, Abebaw Fekadu7. 1. Addis Ababa University, Ethiopia; University of Toronto, Ontario Shores Centre for Mental Health Sciences, Canada. Electronic address: shibreteshome@yahoo.com. 2. Addis Ababa University, Aklilu-Lemma Institute of Pathobiology, Ethiopia. 3. Addis Ababa University, Ethiopia. 4. Addis Ababa University, School of Public Health, Addis Ababa, Ethiopia; WHO Regional Office for Africa, Brazzaville, Congo. 5. Umeå University, Division of Psychiatry, Sweden. 6. Addis Ababa University, Ethiopia; King's College London, Institute of Psychiatry, Health Services and Population Research Department, Centre for Global Mental Health, London, UK. 7. Addis Ababa University, Ethiopia; King's College London, Institute of Psychiatry, Department of Psychological Medicine, London, UK.
Abstract
BACKGROUND: Although the few available studies from LMICs report favorable outcome, the course of schizophrenia is more complex than has been indicated so far. METHODS: A sample of 361 people with a standardized clinical diagnosis of schizophrenia were recruited from a predominantly rural community in Ethiopia and followed up regularly for an average of 10years. Psychiatrists used the Longitudinal Interval Follow-up Evaluation chart to carry out assessment of illness course. Duration of time in clinical remission was the primary outcome. RESULT: About 61.0% of the patients remained under active follow-up, while 18.1% (n=65) were deceased. The mean percentage of follow-up time in complete remission was 28.4% (SD=33.0). Female patients were significantly more likely to have episodic illness course with no inter-episode residual or negative symptoms (χ(2)=6.28, P=0.012). Nearly 14.0% had continuous psychotic symptoms for over 75% of their follow-up time. Only 18.1% achieved complete remission for over 75% of their follow-up time. Later onset of illness was the only significant predictor of achieving full remission for over 50% of follow-up time in a fully adjusted model. Conventional antipsychotic medications were fairly well tolerated in 80% of the patients and 4.2% (n=15) experienced tardive dyskinesia. CONCLUSION: This population-based study is one of the very few long-term outcome studies of schizophrenia in LMICs. The study demonstrated clearly a differential and more favorable course and outcome for female patients but overall course and outcome of schizophrenia appeared less favorable in this setting than has been reported from other LMICs.
BACKGROUND: Although the few available studies from LMICs report favorable outcome, the course of schizophrenia is more complex than has been indicated so far. METHODS: A sample of 361 people with a standardized clinical diagnosis of schizophrenia were recruited from a predominantly rural community in Ethiopia and followed up regularly for an average of 10years. Psychiatrists used the Longitudinal Interval Follow-up Evaluation chart to carry out assessment of illness course. Duration of time in clinical remission was the primary outcome. RESULT: About 61.0% of the patients remained under active follow-up, while 18.1% (n=65) were deceased. The mean percentage of follow-up time in complete remission was 28.4% (SD=33.0). Female patients were significantly more likely to have episodic illness course with no inter-episode residual or negative symptoms (χ(2)=6.28, P=0.012). Nearly 14.0% had continuous psychotic symptoms for over 75% of their follow-up time. Only 18.1% achieved complete remission for over 75% of their follow-up time. Later onset of illness was the only significant predictor of achieving full remission for over 50% of follow-up time in a fully adjusted model. Conventional antipsychotic medications were fairly well tolerated in 80% of the patients and 4.2% (n=15) experienced tardive dyskinesia. CONCLUSION: This population-based study is one of the very few long-term outcome studies of schizophrenia in LMICs. The study demonstrated clearly a differential and more favorable course and outcome for female patients but overall course and outcome of schizophrenia appeared less favorable in this setting than has been reported from other LMICs.
Authors: Roman Kotov; Katherine G Jonas; William T Carpenter; Michael N Dretsch; Nicholas R Eaton; Miriam K Forbes; Kelsie T Forbush; Kelsey Hobbs; Ulrich Reininghaus; Tim Slade; Susan C South; Matthew Sunderland; Monika A Waszczuk; Thomas A Widiger; Aidan G C Wright; David H Zald; Robert F Krueger; David Watson Journal: World Psychiatry Date: 2020-06 Impact factor: 49.548
Authors: Peter Huxley; Anne Krayer; Rob Poole; Louise Prendergast; Sanjaya Aryal; Richard Warner Journal: Brain Behav Date: 2021-05-15 Impact factor: 2.708
Authors: Charlotte Hanlon; Tigist Eshetu; Daniel Alemayehu; Abebaw Fekadu; Maya Semrau; Graham Thornicroft; Fred Kigozi; Debra Leigh Marais; Inge Petersen; Atalay Alem Journal: Int J Ment Health Syst Date: 2017-06-08
Authors: Laura Asher; Abebaw Fekadu; Charlotte Hanlon; Gemechu Mideksa; Julian Eaton; Vikram Patel; Mary J De Silva Journal: PLoS One Date: 2015-11-30 Impact factor: 3.240
Authors: Laura Asher; Mary De Silva; Charlotte Hanlon; Helen A Weiss; Rahel Birhane; Dawit A Ejigu; Girmay Medhin; Vikram Patel; Abebaw Fekadu Journal: Trials Date: 2016-06-24 Impact factor: 2.279
Authors: Laura Asher; Charlotte Hanlon; Rahel Birhane; Alehegn Habtamu; Julian Eaton; Helen A Weiss; Vikram Patel; Abebaw Fekadu; Mary De Silva Journal: BMC Psychiatry Date: 2018-08-03 Impact factor: 3.630